Ethiopia Introduces Malaria Vaccine to Protect Children and Strengthen Health Systems

21 October 2025 | Addis Ababa, Ethiopia - Ethiopia has officially launched the R21/Matrix-M malaria vaccine, becoming the 23rd African country to introduce a malaria vaccine into its routine immunization program. This historic step marks a significant advancement in the country's efforts to reduce the burden of malaria and protect vulnerable populations, particularly children under five.

The vaccine rollout has begun in 58 districts across 9 regions, selected based on WHO's prioritization criteria. These districts represent the highest malaria burden in the country. Over 91,000 children will be targeted in the initial phase, receiving four doses at 6, 7, 9, and 15 months of age.

The vaccine, R21/Matrix-M, one of the malaria vaccines prequalified by WHO, has shown promising results in reducing severe malaria cases and child mortality.

The introduction of the malaria vaccine complements Ethiopia's existing core malaria control strategies, including Indoor Residual Spraying (IRS), Insecticide-Treated Nets (ITNs), and prompt diagnosis and treatment. Together, these interventions aim to reduce hospitalizations, improve school attendance, and decrease work absenteeism among caregivers.

The World Health Organization (WHO) has been a key partner in Ethiopia's malaria vaccine introduction journey, providing support across multiple domains which includes advocacy and awareness-building, technical support for Gavi application, development of implementation guidelines and training materials, facilitation of national and subnational trainings.

"Ethiopia's introduction of the malaria vaccine is a bold and commendable step. It reflects the country's unwavering commitment to protecting its children and building a resilient health system. WHO stands firmly beside Ethiopia in this journey toward malaria elimination." Dr. Francis Chisaka Kasolo, WHO Representative in Ethiopia.

The Honorable State Minister of Health, Dr. Dereje Duguma, emphasized that the internationally approved malaria vaccine offers vital protection for the under five children in the most affected communities. Dr. Dereje urged that while the vaccine supplements existing malaria control efforts, it does not replace them, and it must go hand in hand with continued prevention. Finally, he called on all stakeholders to strengthen malaria control and ensure every child receives this life-saving vaccine.

"Mr. Menaa Mekuriya, Delegate of the South Ethiopia Regional Health Bureau Head, Deputy Head of Bureau, and Head of Health Programs, stated in his opening remarks: "Malaria has disrupted our lives-children were missing school, farmers were unable to work, and families were suffering across the Southern Ethiopia region, particularly in South Omo Zone, where half of the woredas were affected. Today's launch of the malaria vaccine in Turmi Woreda marks a major step forward." He added, "Children under five are especially vulnerable, and this cost-effective vaccine will play a vital role in preventing disease and saving lives. It's a powerful addition to our ongoing health efforts.'"

The launch event brought together national and regional health leaders, community representatives, and global health partners. It also coincided with the mass distribution of long-lasting insecticidal nets, reinforcing Ethiopia's integrated approach to malaria control.

Partners supporting this effort include Gavi, the Vaccine Alliance, UNICEF, Global Fund, PATH, ALMA, Roll Back Malaria Initiative, and the Global Financing Facility (GFF).